Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer.

ABSTRACT: The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics nationwide that provide this service. Ketamine is an FDA-approved drug as an anesthetic but remains unapproved for psychiatric indications, and this status raises a number of short- and long-term safety and efficacy concerns that need to be addressed when implementing and developing this type of clinic. Using a framework of systems, provider, and patient domains, we provide a review of the key challenges in providing ketamine infusions and suggest potential approaches. Under systems issues, we highlight broad stakeholder engagement involving cross-departmental and multidisciplinary considerations, business case development, and delineation of administrative standard o

SUBMITTER: Parikh SV 

PROVIDER: S-EPMC8374924 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature